Every 8-K that Marker Therapeutics, Inc. (MRKR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRKR filings page.
Marker Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved a Charter Amendment to increase authorized common shares from 30,000,000 to 130,000,000. They also re-elected five directors, approved executive compensation on an advisory basis, and ratified CBIZ CPAs P.C. as auditor for the year ending December 31, 2026.
Of 16,673,127 shares outstanding as of the record date, 12,377,857 shares, or 74.24%, were represented. A separate proposal to revise the voting threshold for future changes to common stock did not pass, while an adjournment proposal related to the share increase was approved.
Marker Therapeutics reported 2025 results and clinical progress for its MAR‑T cell therapies. The Phase 1 APOLLO study in relapsed non-Hodgkin lymphoma showed a 66% objective response rate, including 50% complete responses, with a favorable safety profile and dose expansion underway in DLBCL. The company plans another APOLLO data update in the second quarter of 2026 and is preparing a company-sponsored pancreatic cancer trial, supported by strong preclinical data published in Nature Medicine.
Financially, Marker ended December 31, 2025 with $17 million in cash, cash equivalents and restricted cash and expects this to fund operations through the fourth quarter of 2026. Grant revenue was $3.5 million, research and development expenses were $11.8 million, general and administrative expenses were $4.2 million, and net loss was $12.2 million, reflecting a modestly higher loss year over year as the pipeline advanced.
Marker Therapeutics, Inc. has set the date for its 2026 Annual Meeting of Stockholders for May 1, 2026. This meeting date is more than 30 days earlier than the prior year’s annual meeting, which triggers updated notice requirements for shareholder proposals.
The company states that stockholder proposals intended for inclusion in the 2026 proxy statement under SEC Rule 14a-8 must be received at its Houston headquarters by March 9, 2026. The specific record date, time, and location of the meeting will be provided in the upcoming proxy statement.
Marker Therapeutics filed a Form 8-K to report its financial results for the third quarter ended September 30, 2025, and to provide recent corporate updates. The company furnished a press release as Exhibit 99.1, which is incorporated by reference.
The disclosure under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act or Securities Act, limiting associated liabilities. The filing lists the company’s common stock trading under MRKR on The Nasdaq Stock Market and was signed by President and CEO Juan Vera.
Marker Therapeutics (MRKR) appointed Kathryn Penkus Corzo to its Board, effective November 1, 2025. The Board also approved equity awards under the 2020 Equity Incentive Plan.
Ms. Corzo received 147,611 stock options at fair market value, vesting evenly over 36 months, tied to continued Board service. Separately, CEO Dr. Juan Vera was granted 250,000 stock options at fair market value, vesting annually over four years. The company noted no arrangements leading to Ms. Corzo’s selection and no related party transactions, and she will stand for re‑election at the next annual meeting.
Marker Therapeutics, Inc. reported that it has treated the first patient in its Off-the-Shelf (OTS) program evaluating the company’s Multi-Antigen Recognizing (MAR)-T cell therapy. This marks the initial use of its OTS MAR-T product in a clinical setting, an important step in moving the therapy from development into human testing. The update was shared through a press release dated October 6, 2025, which is included as an exhibit to the report.
Marker Therapeutics, Inc. filed a Form 8-K to share new information about its Phase 1 APOLLO study. On August 26, 2025, the company issued a press release describing progress and clinical observations from this study and furnished it as Exhibit 99.1. Marker also updated its corporate presentation, made available on its website and attached as Exhibit 99.2, and prepared a webcast presentation on the APOLLO study results, attached as Exhibit 99.3. The company states that this information is being furnished under Regulation FD and is not deemed filed for liability purposes under the federal securities laws.
Marker Therapeutics disclosed a change in its independent registered public accounting firm: Marcum LLP resigned and CBIZ CPAs P.C. was engaged to serve as the companys auditor for the year ending December 31, 2025, effective with the review of the condensed consolidated financial statements for the quarter ended June 30, 2025. The engagement was approved by the Board of Directors and CBIZ will perform services previously provided by Marcum.
Marcums audit reports for the years ended December 31, 2024 and 2023 did not contain an adverse opinion or disclaimer and were not qualified, except that they included an explanatory paragraph expressing substantial doubt about the companys ability to continue as a going concern. The filing states there were no disagreements and no reportable events between the company and Marcum during the periods covered. A letter from Marcum is filed as Exhibit 16.1.